FT Pharma Pricing and Value Summit

26 September, 2019, New York

Entering a New Era for Market Access

ICON is proud to sponsor the Financial Times Pharma Pricing and Value Summit (New York, Sept 26th), the theme of which is ‘Entering a New Era for Market Access' – focusing on how the pharmaceutical pricing and market access landscape is being transformed by a host of factors.

25% discount for ICON clients

As a lead sponsor, ICON is pleased to offer clients and other third parties, a 25% discount on the registration fee –a savings of $174 off the registration price of $695 for pharma, biotech and healthcare providers. Simply complete the short form to receive your discount code.

The FT Pharma Pricing and Value Summit will explore the future of drug pricing from a balanced perspective. How could the rebate system evolve? Will new powers for Medicare Part D to negotiate drug prices really make a difference to patients? What global factors could change the pricing and market access landscape in the US?

ICON Speaker

Charles A. Stevens, JD, MBA

Vice President , Access, Commercialisation & Communications, ICON

Industry Analysis: Payer Reliance on ICER, Global HTA Reviews and Providers to Determine Value & Coverage Policy

With drug pricing a headline topic, determining product value can be challenging for payers, providers, policy makers and patient consumers.  We will examine updated original research on US payers’ views on ICER assessments and ex-US HTA reviews, and new research results from 100 oncology nurses on drug/treatment value and patient access challenges.

Chuck leads the Access, Commercialisation and Communications practice at ICON. This global service has over 300 life science consultants who support the commercial success of drugs, devices and diagnostics.  Prior to joining ICON, Chuck spent nine years at PAREXEL as the Vice President & General Manager of Reimbursement and Market Access, and held positions of increasing responsibility at Abbott Laboratories, Genetics Institute, Wyeth Oncology, Cell Therapeutics and Cephalon Oncology.  He has significant experience in leading pricing, payer strategy, channel management, pharmacoeconomic modeling, government price reporting, payer marketing, patient advocacy and dossier development for products across many disease states, including hematology, oncology, infectious disease and rare disorders.